Do analysts rate LIXT or OVID?

Ovid Therapeutics has a consensus price target of $5.13, indicating a potential upside of 119.96%. Given Ovid Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Ovid Therapeutics is more favorable than Lixte Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lixte Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ovid Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89

Do analysts recommend LIXT or EVMN?

Evommune has a consensus price target of $45.63, suggesting a potential upside of 301.63%. Given Evommune's stronger consensus rating and higher possible upside, analysts clearly believe Evommune is more favorable than Lixte Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lixte Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Evommune 1 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 2.79

Is LIXT or EVMN more profitable?

Evommune's return on equity of 0.00% beat Lixte Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Lixte Biotechnology N/A -134.91% -95.61% Evommune N/A N/A N/A

Do analysts recommend OCGN or LIXT?

Ocugen presently has a consensus target price of $9.50, indicating a potential upside of 685.12%. Given Ocugen's stronger consensus rating and higher possible upside, research analysts plainly believe Ocugen is more favorable than Lixte Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ocugen 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Lixte Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is OCGN or LIXT more profitable?

Lixte Biotechnology's return on equity of -134.91% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Ocugen N/A -127,987.80% -135.48% Lixte Biotechnology N/A -134.91% -95.61%

Do analysts prefer PBYI or LIXT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Puma Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Lixte Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate LIXT or PRTC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lixte Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, LIXT or PRTC?

Lixte Biotechnology has higher earnings, but lower revenue than PureTech Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lixte Biotechnology N/A N/A -$6.01M -$1.13 N/A PureTech Health $4.66M 91.01 -$109.74M N/A N/A

Is LIXT or PRTC more profitable?

PureTech Health's return on equity of 0.00% beat Lixte Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Lixte Biotechnology N/A -134.91% -95.61% PureTech Health N/A N/A N/A

Lixte Biotechnology (LIXT) Competitors

$7.51 +0.30 (+4.16%)

Closing price 07/2/2026

Extended Trading

$7.51 0.00 (0.00%)

As of 07/2/2026 07:46 PM Eastern

Compare

LIXT vs. OVID, EVMN, OCGN, PBYI, and PRTC

Should you buy Lixte Biotechnology stock or one of its competitors? MarketBeat compares Lixte Biotechnology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lixte Biotechnology include Ovid Therapeutics (OVID), Evommune (EVMN), Ocugen (OCGN), Puma Biotechnology (PBYI), and PureTech Health (PRTC). These companies are all part of the "pharmaceutical products" industry.

How does Lixte Biotechnology compare to Ovid Therapeutics?

Lixte Biotechnology (NASDAQ:LIXT) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

5.1% of Lixte Biotechnology shares are held by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are held by institutional investors. 9.5% of Lixte Biotechnology shares are held by company insiders. Comparatively, 7.0% of Ovid Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Ovid Therapeutics had 4 more articles in the media than Lixte Biotechnology. MarketBeat recorded 4 mentions for Ovid Therapeutics and 0 mentions for Lixte Biotechnology. Ovid Therapeutics' average media sentiment score of 1.60 beat Lixte Biotechnology's score of 0.84 indicating that Ovid Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Lixte Biotechnology	Positive
Ovid Therapeutics	Very Positive

Lixte Biotechnology has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -240.11%. Ovid Therapeutics' return on equity of -22.51% beat Lixte Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lixte Biotechnology	N/A	-134.91%	-95.61%
Ovid Therapeutics	-240.11%	-22.51%	-18.67%

Lixte Biotechnology has higher earnings, but lower revenue than Ovid Therapeutics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Lixte Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.13	N/A
Ovid Therapeutics	$7.25M	59.98	-$17.41M	-$0.29	N/A

Ovid Therapeutics has a consensus price target of $5.13, indicating a potential upside of 119.96%. Given Ovid Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Ovid Therapeutics is more favorable than Lixte Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Lixte Biotechnology has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market. Comparatively, Ovid Therapeutics has a beta of 0.18, indicating that its share price is 82% less volatile than the broader market.

Summary

Ovid Therapeutics beats Lixte Biotechnology on 11 of the 16 factors compared between the two stocks.

How does Lixte Biotechnology compare to Evommune?

Lixte Biotechnology (NASDAQ:LIXT) and Evommune (NYSE:EVMN) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.

Evommune has a consensus price target of $45.63, suggesting a potential upside of 301.63%. Given Evommune's stronger consensus rating and higher possible upside, analysts clearly believe Evommune is more favorable than Lixte Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Evommune	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79

In the previous week, Evommune had 1 more articles in the media than Lixte Biotechnology. MarketBeat recorded 1 mentions for Evommune and 0 mentions for Lixte Biotechnology. Lixte Biotechnology's average media sentiment score of 0.84 beat Evommune's score of 0.00 indicating that Lixte Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Lixte Biotechnology	Positive
Evommune	Neutral

5.1% of Lixte Biotechnology shares are held by institutional investors. 9.5% of Lixte Biotechnology shares are held by insiders. Comparatively, 31.1% of Evommune shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Lixte Biotechnology has higher earnings, but lower revenue than Evommune. Lixte Biotechnology is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.13	N/A
Evommune	$13M	31.48	-$68.87M	-$9.50	N/A

Evommune's return on equity of 0.00% beat Lixte Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lixte Biotechnology	N/A	-134.91%	-95.61%
Evommune	N/A	N/A	N/A

Summary

Evommune beats Lixte Biotechnology on 10 of the 14 factors compared between the two stocks.

How does Lixte Biotechnology compare to Ocugen?

Ocugen (NASDAQ:OCGN) and Lixte Biotechnology (NASDAQ:LIXT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.

Ocugen presently has a consensus target price of $9.50, indicating a potential upside of 685.12%. Given Ocugen's stronger consensus rating and higher possible upside, research analysts plainly believe Ocugen is more favorable than Lixte Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lixte Biotechnology has lower revenue, but higher earnings than Ocugen. Lixte Biotechnology is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.47M	91.74	-$67.85M	-$0.24	N/A
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.13	N/A

Lixte Biotechnology's return on equity of -134.91% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocugen	N/A	-127,987.80%	-135.48%
Lixte Biotechnology	N/A	-134.91%	-95.61%

Ocugen has a beta of 2.18, indicating that its share price is 118% more volatile than the broader market. Comparatively, Lixte Biotechnology has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market.

10.3% of Ocugen shares are held by institutional investors. Comparatively, 5.1% of Lixte Biotechnology shares are held by institutional investors. 4.0% of Ocugen shares are held by insiders. Comparatively, 9.5% of Lixte Biotechnology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Ocugen had 3 more articles in the media than Lixte Biotechnology. MarketBeat recorded 3 mentions for Ocugen and 0 mentions for Lixte Biotechnology. Ocugen's average media sentiment score of 0.96 beat Lixte Biotechnology's score of 0.84 indicating that Ocugen is being referred to more favorably in the media.

Company	Overall Sentiment
Ocugen	Positive
Lixte Biotechnology	Positive

Summary

Ocugen beats Lixte Biotechnology on 10 of the 14 factors compared between the two stocks.

How does Lixte Biotechnology compare to Puma Biotechnology?

Puma Biotechnology (NASDAQ:PBYI) and Lixte Biotechnology (NASDAQ:LIXT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

61.3% of Puma Biotechnology shares are held by institutional investors. Comparatively, 5.1% of Lixte Biotechnology shares are held by institutional investors. 22.2% of Puma Biotechnology shares are held by company insiders. Comparatively, 9.5% of Lixte Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Puma Biotechnology had 2 more articles in the media than Lixte Biotechnology. MarketBeat recorded 2 mentions for Puma Biotechnology and 0 mentions for Lixte Biotechnology. Puma Biotechnology's average media sentiment score of 0.94 beat Lixte Biotechnology's score of 0.84 indicating that Puma Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Puma Biotechnology	Positive
Lixte Biotechnology	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Puma Biotechnology has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market. Comparatively, Lixte Biotechnology has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market.

Puma Biotechnology has higher revenue and earnings than Lixte Biotechnology. Lixte Biotechnology is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$228.40M	1.78	$31.11M	$0.48	16.63
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.13	N/A

Puma Biotechnology has a net margin of 10.69% compared to Lixte Biotechnology's net margin of 0.00%. Puma Biotechnology's return on equity of 20.30% beat Lixte Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	10.69%	20.30%	12.05%
Lixte Biotechnology	N/A	-134.91%	-95.61%

Summary

Puma Biotechnology beats Lixte Biotechnology on 12 of the 13 factors compared between the two stocks.

How does Lixte Biotechnology compare to PureTech Health?

Lixte Biotechnology (NASDAQ:LIXT) and PureTech Health (NASDAQ:PRTC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends, media sentiment and valuation.

PureTech Health's return on equity of 0.00% beat Lixte Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lixte Biotechnology	N/A	-134.91%	-95.61%
PureTech Health	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

5.1% of Lixte Biotechnology shares are owned by institutional investors. Comparatively, 0.0% of PureTech Health shares are owned by institutional investors. 9.5% of Lixte Biotechnology shares are owned by company insiders. Comparatively, 5.3% of PureTech Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Lixte Biotechnology has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market. Comparatively, PureTech Health has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market.

Lixte Biotechnology has higher earnings, but lower revenue than PureTech Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.13	N/A
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A

In the previous week, Lixte Biotechnology's average media sentiment score of 0.84 beat PureTech Health's score of 0.00 indicating that Lixte Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Lixte Biotechnology	Positive
PureTech Health	Neutral

Summary

Lixte Biotechnology beats PureTech Health on 5 of the 8 factors compared between the two stocks.

Get Lixte Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LIXT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LIXT vs. The Competition

Export

Metric	Lixte Biotechnology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$112.80M	$3.67B	$6.87B	$12.26B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-6.65	21.48	27.14	23.64
Price / Sales	N/A	170.08	517.08	89.45
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	7.15	7.88	10.28	6.07
Net Income	-$6.01M	$23.86M	$3.60B	$331.99M
7 Day Performance	N/A	-3.82%	-1.27%	-0.63%
1 Month Performance	12.93%	-2.61%	-0.37%	-2.00%
1 Year Performance	82.73%	32.79%	18.30%	13.62%

Lixte Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LIXT Lixte Biotechnology	0.2761 of 5 stars	$7.51 +4.2%	N/A	+75.1%	$112.80M	N/A	N/A	4	Gap Up
OVID Ovid Therapeutics	2.3054 of 5 stars	$2.38 -1.2%	$5.13 +115.3%	+236.2%	$449.80M	$7.25M	N/A	60	News Coverage Positive News Analyst Forecast Gap Up
EVMN Evommune	3.2097 of 5 stars	$11.44 -6.4%	$45.63 +298.7%	N/A	$440.14M	$13M	N/A	45	Positive News
OCGN Ocugen	2.4191 of 5 stars	$1.29 -0.8%	$9.50 +636.4%	+8.0%	$440.08M	$4.41M	N/A	80	Upcoming Earnings
PBYI Puma Biotechnology	0.9871 of 5 stars	$7.87 -8.3%	N/A	+134.7%	$436.72M	$228.40M	16.40	200	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LIXT) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lixte Biotechnology (LIXT) Competitors

LIXT vs. OVID, EVMN, OCGN, PBYI, and PRTC

How does Lixte Biotechnology compare to Ovid Therapeutics?

Summary

How does Lixte Biotechnology compare to Evommune?

Summary

How does Lixte Biotechnology compare to Ocugen?

Summary

How does Lixte Biotechnology compare to Puma Biotechnology?

Summary

How does Lixte Biotechnology compare to PureTech Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIXT vs. The Competition

Lixte Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lixte Biotechnology (LIXT) Competitors

LIXT vs. OVID, EVMN, OCGN, PBYI, and PRTC

How does Lixte Biotechnology compare to Ovid Therapeutics?

Do institutionals and insiders believe in LIXT or OVID?

Does the media refer more to LIXT or OVID?

Is LIXT or OVID more profitable?

Which has better valuation & earnings, LIXT or OVID?

Do analysts rate LIXT or OVID?

Which has more volatility and risk, LIXT or OVID?

Summary

How does Lixte Biotechnology compare to Evommune?

Do analysts recommend LIXT or EVMN?

Does the media favor LIXT or EVMN?

Do institutionals & insiders have more ownership in LIXT or EVMN?

Which has preferable earnings and valuation, LIXT or EVMN?

Is LIXT or EVMN more profitable?

Summary

How does Lixte Biotechnology compare to Ocugen?

Do analysts recommend OCGN or LIXT?

Which has stronger valuation & earnings, OCGN or LIXT?

Is OCGN or LIXT more profitable?

Which has more risk and volatility, OCGN or LIXT?

Do insiders and institutionals believe in OCGN or LIXT?

Does the media refer more to OCGN or LIXT?

Summary

How does Lixte Biotechnology compare to Puma Biotechnology?

Do institutionals & insiders believe in PBYI or LIXT?

Does the media prefer PBYI or LIXT?

Do analysts prefer PBYI or LIXT?

Which has more risk and volatility, PBYI or LIXT?

Which has stronger valuation & earnings, PBYI or LIXT?

Is PBYI or LIXT more profitable?

Summary

How does Lixte Biotechnology compare to PureTech Health?

Is LIXT or PRTC more profitable?

Do analysts rate LIXT or PRTC?

Do institutionals & insiders believe in LIXT or PRTC?

Which has more risk and volatility, LIXT or PRTC?

Which has better earnings and valuation, LIXT or PRTC?

Does the media prefer LIXT or PRTC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIXT vs. The Competition

Lixte Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools